The department of Internal Medicine of the Radboudumc is extremely happy to announce that on January 1st, 2021 Prof. dr. Willem Mulder (1976) will be joining the department, together with some of his researchers. Mulder, who will hold a parttime appointment at Eindhoven University of Technology, will serve as the bridge between the Radboudumc and TU/e.
After obtaining a master’s degree in chemistry from the Utrecht University and a Ph.D. in biomedical engineering from the Eindhoven University of Technology, Mulder was recruited to the Icahn School of Medicine at Mount Sinai (ISMMS) in New York in 2006. Mulder currently is a tenured professor in the Biomedical Engineering and Imaging Institute where he directs ISMMS’s Nanomedicine Program. This research program focuses on the development and translation of nanomedicine and immuno-imaging approaches for cancer, cardiovascular diseases and organ transplantation. Most notably, Mulder pioneered a disease treatment paradigm involving the regulation of innate immune responses using nanobiologic therapeutics. Mulder is the principal investigator of multiple National Institutes of Health grants.
In addition to his position at Mount Sinai, Mulder held a secondary professor appointment at the Amsterdam UMC from 2012 to 2018, and currently at the Eindhoven University of Technology (TU/e). In 2013, Mulder received a VIDI grant and in 2018 he was awarded a VICI grant, both from the Dutch Research Council (NWO, ZonMW). Mulder has published more than 165 scientific publications in top scientific journals, including Nature Nanotechnology, Nature Reviews Drug Discovery, Nature Biomedical Engineering, Science Translational Medicine, Cell, Immunity, etc. His H-index is 69 and his work has been cited nearly 14.000 times. Mulder is a scientific founder of Trained Therapeutix Discovery, a biotech startup that aims to treat today’s most detrimental diseases with novel nanobiologic therapeutics.
The research of the department of Internal Medicine is focused on inflammation and the immune system in various diseases. Mulder’s research will focus on therapeutically regulating and imaging the immune system with innovative nanotechnology approaches. In addition to the Radboudumc, he will have an appointment at TU/e’s department of biomedical engineering. This will enable an exciting opportunity for collaboration and integration of the strengths of both departments and institutes.
The immuno-oncology revolution and the current COVID-19 pandemic underscore the importance of translational immunology research and biomedical engineering. Radboudumc and TU/e are frontrunners in these respective fields. At Mount Sinai, Mulder built a unique translational research program that integrates nanotechnology, immunology, disease model and in vivo imaging to yield innovative immunotherapy strategies. By moving his research activities to the Netherlands, Mulder will serve as the bridge between the Radboudumc and TU/e.
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Real-time dialogue with a dreaming person is possible25 February 2021
Dreams take us to what feels like a different reality. They also happen while we're fast asleep. So, you might not expect that a person in the midst of a vivid dream would be able to perceive questions and provide answers to them. But a new international study shows that, in fact, they can.read more
Vulnerable Nijmegen citizens less likely to visit GP physically due to corona23 February 2021
The COVID-19 pandemic in 2020 in Nijmegen and the surrounding area led to a substantial decrease in GP consultations for patients with chronic physical health problems.read more
SATB1 - Three classes of mutations and their unique rare diseases18 February 2021
Recent advances in DNA sequencing technologies have made it possible to uncover the causes of multiple rare diseases. A new collaborative study describes how three classes of mutation within the same gene result in different neurodevelopmental disorders.read more
New Physical, Mental, and Cognitive Problems 1-year Post-ICU18 February 2021
Half of the Intensive Care Unit (ICU) survivors suffer from new physical, mental and/or cognitive problems one year after ICU admission. This is evident from the large-scale MONITOR-IC study led by the Radboudumc.read more
Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection17 February 2021
In a review in Cell Mihai Netea, Frank van de Veerdonk, Reinout van Crevel and Jorge Dominguez Andres propose that induction of trained immunity by whole-microorganism vaccines may represent an important tool for reducing susceptibility to and severity of SARS-CoV-2.read more